Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.

NCT ID NCT07729241

Ongoing Knowledge-focused Sponsor: Groupe Hospitalier Pitie-Salpetriere Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing those vaccinated around the time of immunotherapy initiation with those who were not. The goal is to see if the vaccine timing might influence overall survival, cancer-related death, or disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA COVID-19 vaccination
What this could lead to: If a link is found, it could suggest that timing COVID-19 vaccination with immunotherapy may improve survival for cancer patients.
What could go wrong: This is an observational study, so it cannot prove cause and effect. Results may be influenced by other factors, and the benefit, if any, may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer COVID-19 neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER COVID-19 VACCINATION IMMUNE CHECKPOINT INHIBITORS SURVIVAL

Contacts and locations

Locations

Hôpital Pitié Salpêtrière / CIC-2503, Paris

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.